
Psilocybin Outperforms SSRIs in Long-Term Depression Treatment
A recent study from Imperial College London has revealed a new potential treatment for major depression, psilocybin.
Category
8 stories in this category.

A recent study from Imperial College London has revealed a new potential treatment for major depression, psilocybin.

In addition to the raise, Dr. Rick Doblin of MAPS has joined Numinus as an unpaid strategic advisor.

The FDA has accepted Lykos Therapeutics' MDMA-assisted therapy application and could transform mental health treatment.

The US Department of Veteran Affairs will fund research for psychedelics-based therapies for the first time.

Following their submission for FDA approval for MDMA-based therapy in December, MAPS has rebranded to Lykos Therapeutics.

This marks a significant moment in the widespread acceptance of using psychedelics for therapeutic use.

Steve Cohen's investment boosts psychedelic research in biopharma, with top billionaires reshaping mental health care.

Harvard explores psychedelics with $16M from ex-Tesla director Antonio Gracias.